|
1
|
Roviello G, Ravelli A, Polom K, Petrioli
R, Marano L, Marrelli D, Roviello F and Generali D: Apatinib: A
novel receptor tyrosine kinase inhibitor for the treatment of
gastric cancer. Cancer Lett. 372:187–191. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cancer Genome Atlas Research Network, .
Comprehensive molecular characterization of gastric adenocarcinoma.
Nature. 513:202–209. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cristescu R, Lee J, Nebozhyn M, Kim KM,
Ting JC, Wong SS, Liu J, Yue YG, Wang J, Yu K, et al: Molecular
analysis of gastric cancer identifies subtypes associated with
distinct clinical outcomes. Nat Med. 21:449–456. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Espelin CW, Leonard SC, Geretti E, Wickham
TJ and Hendriks BS: Dual HER2 targeting with trastuzumab and
liposomal-encapsulated doxorubicin (MM-302) demonstrates
synergistic antitumor activity in breast and gastric cancer. Cancer
Res. 76:1517–1527. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gravalos C and Jimeno A: HER2 in gastric
cancer: A new prognostic factor and a novel therapeutic target. Ann
Oncol. 19:1523–1529. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bang YJ, Van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): A phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen K, Yang D, Li X, Sun B, Song F, Cao
W, Brat DJ, Gao Z, Li H, Liang H, et al: Mutational landscape of
gastric adenocarcinoma in Chinese: Implications for prognosis and
therapy. Proc Natl Acad Sci USA. 112:1107–1112. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Park H, Cho SY, Kim H, Na D, Han JY, Chae
J, Park C, Park OK, Min S, Kang J, et al: Genomic alterations in
BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer.
Proc Natl Acad Sci USA. 112:12492–12497. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hutchinson L: Biomarkers:
ctDNA-identifying cancer before it is clinically detectable. Nat
Rev Clin Oncol. 12:3722015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Taniguchi K, Uchida J, Nishino K, Kumagai
T, Okuyama T, Okami J, Higashiyama M, Kodama K, Imamura F and Kato
K: Quantitative detection of EGFR mutations in circulating tumor
DNA derived from lung adenocarcinomas. Clin Cancer Res.
17:7808–7815. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kinugasa H, Nouso K, Tanaka T, Miyahara K,
Morimoto Y, Dohi C, Matsubara T, Okada H and Yamamoto K: Droplet
digital PCR measurement of HER2 in patients with gastric cancer. Br
J Cancer. 112:1652–1655. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim HR, Lee SY, Hyun DS, Lee MK, Lee HK,
Choi CM, Yang SH, Kim YC, Lee YC, Kim SY, et al: Detection of EGFR
mutations in circulating free DNA by PNA-mediated PCR clamping. J
Exp Clin Cancer Res. 32:502013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Douillard JY, Ostoros G, Cobo M, Ciuleanu
T, Cole R, McWalter G, Walker J, Dearden S, Webster A, Milenkova T
and McCormack R: Gefitinib treatment in EGFR mutated caucasian
NSCLC: Circulating-free tumor DNA as a surrogate for determination
of EGFR status. J Thorac Oncol. 9:1345–1353. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hamakawa T, Kukita Y, Kurokawa Y, Miyazaki
Y, Takahashi T, Yamasaki M, Miyata H, Nakajima K, Taniguchi K,
Takiguchi S, et al: Monitoring gastric cancer progression with
circulating tumour DNA. Br J Cancer. 112:352–356. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shoda K, Ichikawa D, Fujita Y, Masuda K,
Hiramoto H, Hamada J, Arita T, Konishi H, Komatsu S, Shiozaki A, et
al: Monitoring the HER2 copy number status in circulating tumor DNA
by droplet digital PCR in patients with gastric cancer. Gastric
Cancer. 20:126–135. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kukita Y, Matoba R, Uchida J, Hamakawa T,
Doki Y, Imamura F and Kato K: High-fidelity target sequencing of
individual molecules identified using barcode sequences: De novo
detection and absolute quantitation of mutations in plasma
cell-free DNA from cancer patients. DNA Res. 22:269–277. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Washington K: 7th Edition of the AJCC
cancer staging manual: Stomach. Ann Surg Oncol. 17:3077–3079. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nagahashi M, Shimada Y, Ichikawa H,
Nakagawa S, Sato N, Kaneko K, Homma K, Kawasaki T, Kodama K, Lyle
S, et al: Formalin-fixed paraffin-embedded sample conditions for
deep next generation sequencing. J Surg Res. 220:125–132. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang X, Chu Y, Zhang R, Han Y, Zhang L, Fu
Y, Li D, Peng R, Li D, Ding J, et al: Technical validation of a
next-generation sequencing assay for detecting clinically relevant
levels of breast cancer-related single-nucleotide variants and copy
number variants using simulated cell-free DNA. J Mol Diagn.
19:525–536. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cibulskis K, Lawrence MS, Carter SL,
Sivachenko A, Jaffe D, Sougnez C, Gabriel S, Meyerson M, Lander ES,
Getz G, et al: Sensitive detection of somatic point mutations in
impure and heterogeneous cancer samples. Nat Biotechnol.
31:213–219. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li J, Lupat R, Amarasinghe KC, Thompson
ER, Doyle MA, Ryland GL, Tothill RW, Halgamuge SK, Campbell IG and
Gorringe KL: CONTRA: Copy number analysis for targeted
resequencing. Bioinformatics. 28:1307–1313. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen K, Wallis JW, McLellan MD, Larson DE,
Kalicki JM, Pohl CS, McGrath SD, Wendl MC, Zhang Q, Locke DP, et
al: BreakDancer: An algorithm for high-resolution mapping of
genomic structural variation. Nat Methods. 6:677–681. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Robinson JT, Thorvaldsdottir H, Winckler
W, Guttman M, Lander ES, Getz G and Mesirov JP: Integrative
genomics viewer. Nat Biotechnol. 29:24–26. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yuan ZY, Gao SG, Mu JW, Xue Q, Mao YS,
Wang DL, Zhao J, Gao YS, Huang JF and He J: Prognostic value of
preoperative serum lactate dehydrogenase in thymic carcinoma. J
Thoracic Dis. 8:2464–2472. 2016. View Article : Google Scholar
|
|
25
|
Wang Y, Zhao C, Chang L, Jia R, Liu R,
Zhang Y, Gao X, Li J, Chen R, Xia X, Bulbul A, et al: Circulating
tumor DNA analyses predict progressive disease and indicate
trastuzumab-resistant mechanism in advanced gastric cancer.
EBioMedicine. 43:261–269. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yu J, Wu WK, Li X, He J, Li XX, Ng SS, Yu
C, Gao Z, Yang J, Li M, et al: Novel recurrently mutated genes and
a prognostic mutation signature in colorectal cancer. Gut.
64:636–645. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Voss MH, Hakimi AA, Pham CG, Brannon AR,
Chen YB, Cunha LF, Akin O, Liu H, Takeda S, Scott SN, et al: Tumor
genetic analyses of patients with metastatic renal cell carcinoma
and extended benefit from mTOR inhibitor therapy. Clin Cancer Res.
20:1955–1964. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Drilon A, Wang L, Arcila ME,
Balasubramanian S, Greenbowe JR, Ross JS, Stephens P, Lipson D,
Miller VA, Kris MG, et al: Broad, Hybrid Capture-based
next-generation sequencing identifies actionable genomic
alterations in lung adenocarcinomas otherwise negative for such
alterations by other genomic testing approaches. Clin Cancer Res.
21:3631–3639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Murtaza M, Dawson SJ, Pogrebniak K, Rueda
OM, Provenzano E, Grant J, Chin SF, Tsui DWY, Marass F, Gale D, et
al: Multifocal clonal evolution characterized using circulating
tumour DNA in a case of metastatic breast cancer. Nat Commun.
6:87602015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jacoby MA, Duncavage EJ and Walter MJ:
Implications of tumor clonal heterogeneity in the era of
next-generation sequencing. Trends Cancer. 1:231–241. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Abbosh C, Birkbak NJ, Wilson GA,
Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA,
Veeriah S, Rosenthal R, et al: Phylogenetic ctDNA analysis depicts
early-stage lung cancer evolution. Nature. 545:446–451. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wan JCM, Massie C, Garcia-Corbacho J,
Mouliere F, Brenton JD, Caldas C, Pacey S, Baird R and Rosenfeld N:
Liquid biopsies come of age: Towards implementation of circulating
tumour DNA. Nat Rev Cancer. 17:223–238. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Phallen J, Sausen M, Adleff V, Leal A,
Hruban C, White J, Anagnostou V, Fiksel J, Cristiano S, Papp E, et
al: Direct detection of early-stage cancers using circulating tumor
DNA. Sci Transl Med. 9(pii): eaan24152017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zehir A, Benayed R, Shah RH, Syed A,
Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, et
al: Mutational landscape of metastatic cancer revealed from
prospective clinical sequencing of 10,000 patients. Nat Med.
23:703–713. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Müller V, Clemens M, Jassem J, Al-Sakaff
N, Auclair P, Nüesch E, Holloway D, Shing M and Bang YJ: Long-term
trastuzumab (Herceptin®) treatment in a continuation
study of patients with HER2-positive breast cancer or HER2-positive
gastric cancer. BMC Cancer. 18:2952018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Oyama K, Fushida S, Tsukada T, Kinoshita
J, Watanabe T, Shoji M, Nakanuma S, Okamoto K, Sakai S, Makino I,
et al: Evaluation of serum HER2-ECD levels in patients with gastric
cancer. J Gastroenterol. 50:41–45. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shi HZ, Wang YN, Huang XH, Zhang KC, Xi
HQ, Cui JX, Liu GX, Liang WT, Wei B and Chen L: Serum HER2 as a
predictive biomarker for tissue HER2 status and prognosis in
patients with gastric cancer. World J Gastroenterol. 23:1836–1842,
2017.30. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dawson SJ, Tsui DW, Murtaza M, Biggs H,
Rueda OM, Chin SF, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B,
et al: Analysis of circulating tumor DNA to monitor metastatic
breast cancer. N Engl J Med. 368:1199–1209. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tie J, Wang Y, Tomasetti C, Li L, Springer
S, Kinde I, Silliman N, Tacey M, Wong HL, Christie M, et al:
Circulating tumor DNA analysis detects minimal residual disease and
predicts recurrence in patients with stage II colon cancer. Sci
Transl Med. 8:346ra3922016. View Article : Google Scholar
|
